Trials in palliative treatment-have the goal posts been moved?

The Lancet Oncology

Volumn 9, Issue 3, 2008, Pages 186-187

  Kirkbride, Peter ^a   Tannock, Ian F ^b  

^a WESTON PARK HOSPITAL   (United Kingdom)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

DOCETAXEL; ERLOTINIB; FLUOROURACIL; GEMCITABINE; MITOXANTRONE;

ADVANCED CANCER; CANCER CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DRUG INDUSTRY; FOOD AND DRUG ADMINISTRATION; HUMAN; KIDNEY CARCINOMA; LETTER; LUNG SMALL CELL CANCER; METASTASIS; MONOTHERAPY; PANCREAS CANCER; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; QUALITY OF LIFE; SYMPTOM; UNSPECIFIED SIDE EFFECT; BIOASSAY; MALE; MOTIVATION; NEOPLASM; PALLIATIVE THERAPY; PSYCHOLOGICAL ASPECT;

CLINICAL TRIALS AS TOPIC; ENDPOINT DETERMINATION; GOALS; HUMANS; MALE; NEOPLASMS; PALLIATIVE CARE; QUALITY OF LIFE;

EID: 40749090410     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(08)70041-X     Document Type: Letter

References (15)

1. Porzolt F. Goals of palliative cancer therapy: scope of the problem. Cancer Treat Rev 19 suppl A (1993) 3-14
2. Burris H., Moore M., Anderson J., et al. Improvement in survival and clinical benefits with gemcitabine as first line therapy for patients with advanced pancreas cancer: a randomised trial. J Clin Oncol 15 (1997) 2403-2413
3. Hudes G., Carducci M., Tomczak P., et al. Temsirolimus, interferon alfa or both for advanced renal cell carcinoma. N Engl Med 356 (2007) 2271-2281
4. Moore M., Goldstein D., Hamm J., et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 25 (2007) 1960-1966
5. Tannock I., Osoba D., Stockler R., et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol 14 (1996) 1756-1764
6. Tannock I., de Wit R., Berry W., et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351 (2004) 1502-1512
7. Petrylak D., Tangen C., Hussain M., et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351 (2004) 1513-1520
8. Macbeth F., Bolger J., and Hopwood P. Randomized trial of palliative two-fraction versus more intensive 13-fraction radiotherapy for patients with inoperable non-small cell lung cancer and good performance status. Medical Research Council Lung Cancer Working Party. Clin Oncol (R Coll Radiol) 8 (1996) 167-175
9. Bezjak A., Dixon P., and Brundage M. Randomized phase III trial of single versus fractionated thoracic radiation in the palliation of patients with lung cancer (NCIC CTG SC.15). Int J Radiat Oncol Biol Phys 54 (2002) 719-728
10. Sundstrøm S., Bremnes R., and Aasebø U. Hypofractionated palliative radiotherapy (17 Gy per two fractions) in advanced non-small-cell lung carcinoma is comparable to standard fractionation for symptom control and survival: a national phase III trial. J Clin Oncol 22 (2004) 801-810
11. Slotman B., Faivre-Finn C., Kramer G., et al. Prophylactic cranial irradiation in extensive small-cell lung cancer. N Engl J Med 357 (2007) 664-672
12. Morgan G., Ward R., and Barton M. The contribution of cytotoxic chemotherapy to 5-year survival in adult malignancies. Clin Oncol (R Coll Radiol) 16 (2004) 549-560
13. Joly F., Vardy J., Pintilie M., and Tannock I. Quality of life and/or symptom control in randomized clinical trials for patients with advanced cancer. Ann Oncol 18 (2007) 1935-1942
14. Slevin M., Stubbs L., Plant H., et al. Attitudes to chemotherapy: comparing views of patients with cancer with those of doctors, nurses and general public. BMJ 300 (1990) 1458-1460
15. Jansen S., Kievit J., Nooij M., et al. Patients' preferences for adjuvant chemotherapy in early-stage breast cancer: is treatment worthwhile?. Br J Cancer 84 (2001) 1577-1585